Provider review
Sunlight review
By The Dose Brief Desk · Updated
Low starting headlines come with a four-week supply description and a prescription-processing refund cutoff.
Not rated. This review examines published program information; it is not a firsthand treatment review.
At a glance
- Semaglutide
- From $88/month on the cited offer; full commitment unconfirmed
- Tirzepatide
- From $157/month on the cited offer; full commitment unconfirmed
- Availability
- Sunlight advertises all 50 states, subject to clinical and pharmacy availability.
- Treatment formats
- Compounded semaglutide and tirzepatide programs.
Offer describes four-week supply. Confirm purchase term, actual billing cadence and promotion conditions.
A four-week supply is not a calendar month
Sunlight’s t3 offer advertises semaglutide from $88 and tirzepatide from $157 a month while describing four weeks of medication. Confirm whether billing follows four-week shipments or calendar months. Thirteen four-week periods fit into 52 weeks, so the distinction affects an annual budget.
What the offer includes
The page describes medication, unlimited video visits and shipping without an extra membership fee. A seasonal discount also appears. The full commitment behind the starting amounts was not established, so request the upfront total and the rate after the promotion.
Named pharmacy partners help with follow-up questions
Sunlight lists partners including Belmar, Strive, Epiq, Casa Pharma Rx, Pharmacy Hub and Foothills. A partner list is useful background, but patients still need to know which pharmacy supplies their own formulation and whom to contact about a shipment.
The prescription cutoff matters
The offer describes medical-denial refund provisions but says medication becomes nonrefundable once the prescription is written and sent. Cancellation requires contacting the service. Ask when renewal prescriptions are processed so a cancellation request arrives before the order can no longer be stopped.
What stands out
- Named pharmacy partners and included video visits
- Refund processing point is described
What to check
- Starting prices lack a fully verified commitment
- Four-week supply and monthly wording need reconciliation
Sources and review scope
Public information checked in October 2026. Prices and eligibility can change. We have not enrolled in treatment, independently tested medications or verified the licenses of the clinicians and pharmacies involved in an individual prescription. Compounded medications are not FDA-approved; studies of approved brands do not establish that a compounded product has the same safety or effectiveness.